Abstract
Pharmacological modulation of serum lipid levels is a powerful means of favourably modifying the risk and incidence of coronary disease. High density lipoproteins (HDL) exert a beneficial influence on atherosclerotic disease, in part by modulating blood lipid metabolism. Three factors have contributed to the growing interest in HDL as a therapeutic target. Firstly, recent, if limited, clinical trials have demonstrated the cardiovascular benefits of modulating HDL. Secondly, on-going studies have clarified several aspects of HDL metabolism and opened new avenues for pharmacological intervention. Thirdly, the WHO foresees an enormous global increase in the incidence of type 2 diabetes, as well as a related disorder, the metabolic syndrome. Both have, as their primary complication, cardiovascular disease whilst one of the principal lipid disorders is a reduction in HDL. Thus for several cogent reasons, HDL has become a primary target for drug development. The review covers our understanding of HDL metabolism, and notably the contribution of recent studies, in the context of potential sites for intervention. The rationale for targeting such sites, and available human and animal data on the cardiovascular consequences of modulating their activities, is discussed. Finally, the current status of drugs developed with a view to influencing HDL metabolism is presented.
Keywords: lipoproteins, atherosclerosis, cholesterol, triglycerides, risk, hdl, ldl, vascular, gene
Current Medicinal Chemistry
Title: A Helping Hand for the Good Guy; Novel Pharmacological Approaches for Augmenting the Cardiovascular Benefits of High Density Lipoproteins
Volume: 10 Issue: 11
Author(s): Richard W. James
Affiliation:
Keywords: lipoproteins, atherosclerosis, cholesterol, triglycerides, risk, hdl, ldl, vascular, gene
Abstract: Pharmacological modulation of serum lipid levels is a powerful means of favourably modifying the risk and incidence of coronary disease. High density lipoproteins (HDL) exert a beneficial influence on atherosclerotic disease, in part by modulating blood lipid metabolism. Three factors have contributed to the growing interest in HDL as a therapeutic target. Firstly, recent, if limited, clinical trials have demonstrated the cardiovascular benefits of modulating HDL. Secondly, on-going studies have clarified several aspects of HDL metabolism and opened new avenues for pharmacological intervention. Thirdly, the WHO foresees an enormous global increase in the incidence of type 2 diabetes, as well as a related disorder, the metabolic syndrome. Both have, as their primary complication, cardiovascular disease whilst one of the principal lipid disorders is a reduction in HDL. Thus for several cogent reasons, HDL has become a primary target for drug development. The review covers our understanding of HDL metabolism, and notably the contribution of recent studies, in the context of potential sites for intervention. The rationale for targeting such sites, and available human and animal data on the cardiovascular consequences of modulating their activities, is discussed. Finally, the current status of drugs developed with a view to influencing HDL metabolism is presented.
Export Options
About this article
Cite this article as:
James W. Richard, A Helping Hand for the Good Guy; Novel Pharmacological Approaches for Augmenting the Cardiovascular Benefits of High Density Lipoproteins, Current Medicinal Chemistry 2003; 10 (11) . https://dx.doi.org/10.2174/0929867033457665
DOI https://dx.doi.org/10.2174/0929867033457665 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases
Current Medicinal Chemistry Depression and Vascular Disease: Conceptual Issues, Relationships and Clinical Implications
Vascular Disease Prevention (Discontinued) Engineering Antibodies for Therapy
Current Pharmaceutical Biotechnology Targeting Cytokines for Morphine Tolerance: A Narrative Review
Current Neuropharmacology Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain
Current Neuropharmacology Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Signal Transduction via Cannabinoid Receptors
CNS & Neurological Disorders - Drug Targets The Prospect for Type 2 Diabetes Mellitus Combined with Exercise and Synbiotics: A Perspective
Current Diabetes Reviews Anticoagulant Therapy in Pregnant Patients with Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Scaffolds for Blocking Protein-Protein Interactions
Current Topics in Medicinal Chemistry Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature
Current Pharmaceutical Design Updating the Chemistry and Biology of Cannabinoid CB2 Receptor – Specific Inverse Agonists
Current Topics in Medicinal Chemistry Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design Synthesis and Pharmacological Evaluation of Novel 4-Alkyl-5-thien-2’-yl Pyrazole Carboxamides
Central Nervous System Agents in Medicinal Chemistry Biotherapy for Autoimmune Liver Diseases
Current Pharmaceutical Biotechnology 11 Years of Cyanopyrrolidines as DPP-IV Inhibitors
Current Topics in Medicinal Chemistry Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry Estrogen, A Double-Edged Sword: Modulation of TH1- and TH2-Mediated Inflammations by Differential Regulation of TH1 / TH2 Cytokine Production
Current Drug Targets - Inflammation & Allergy Strategies for Targeting Lentiviral Vectors
Current Gene Therapy